These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22465904)

  • 1. Evaluation of oral zinc sulfate effect on obsessive-compulsive disorder: a randomized placebo-controlled clinical trial.
    Sayyah M; Olapour A; Saeedabad Ys; Yazdan Parast R; Malayeri A
    Nutrition; 2012 Sep; 28(9):892-5. PubMed ID: 22465904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.
    Diniz JB; Shavitt RG; Fossaluza V; Koran L; Pereira CA; Miguel EC
    J Clin Psychopharmacol; 2011 Dec; 31(6):763-8. PubMed ID: 22020357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder.
    Sayyah M; Boostani H; Pakseresht S; Malayeri A
    Psychiatry Res; 2011 Oct; 189(3):403-6. PubMed ID: 21329988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of Obsessive-Compulsive Disorder.
    Sayyah M; Boostani H; Pakseresht S; Malayeri A
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):362-5. PubMed ID: 20035818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Ringold AL; Elliott MA
    J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial.
    Ghobadian A; Mokhtari S; Shariati B; Kamalzadeh L; Shati M; Eftekhar Ardebili M; Yarahmadi M; Shalbafan M
    BMC Pharmacol Toxicol; 2022 Sep; 23(1):73. PubMed ID: 36167636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of fluoxetine on various subtypes of obsessive-compulsive disorder.
    Farnam A; Goreishizadeh MA; Farhang S
    Arch Iran Med; 2008 Sep; 11(5):522-5. PubMed ID: 18759519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial.
    Reddihough DS; Marraffa C; Mouti A; O'Sullivan M; Lee KJ; Orsini F; Hazell P; Granich J; Whitehouse AJO; Wray J; Dossetor D; Santosh P; Silove N; Kohn M
    JAMA; 2019 Oct; 322(16):1561-1569. PubMed ID: 31638682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?
    Koran LM; Cain JW; Dominguez RA; Rush AJ; Thiemann S
    Am J Psychiatry; 1996 Nov; 153(11):1450-4. PubMed ID: 8890679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial.
    Shalbafan M; Malekpour F; Tadayon Najafabadi B; Ghamari K; Dastgheib SA; Mowla A; Shirazi E; Eftekhar Ardebili M; Ghazizadeh-Hashemi M; Akhondzadeh S
    J Psychopharmacol; 2019 Nov; 33(11):1407-1414. PubMed ID: 31575326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
    Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study.
    Bergeron R; Ravindran AV; Chaput Y; Goldner E; Swinson R; van Ameringen MA; Austin C; Hadrava V
    J Clin Psychopharmacol; 2002 Apr; 22(2):148-54. PubMed ID: 11910259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: a randomized double blind placebo controlled clinical trial.
    Sahraian A; Bigdeli M; Ghanizadeh A; Akhondzadeh S
    J Affect Disord; 2014 Sep; 166():201-5. PubMed ID: 25012432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial.
    Mowla A; Boostani S; Dastgheib SA
    J Clin Psychopharmacol; 2016 Dec; 36(6):720-723. PubMed ID: 27811556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoxetine has no marked effect on tic symptoms in patients with Tourette's syndrome: a double-blind placebo-controlled study.
    Scahill L; Riddle MA; King RA; Hardin MT; Rasmusson A; Makuch RW; Leckman JF
    J Child Adolesc Psychopharmacol; 1997; 7(2):75-85. PubMed ID: 9334893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.
    Kordon A; Wahl K; Koch N; Zurowski B; Anlauf M; Vielhaber K; Kahl KG; Broocks A; Voderholzer U; Hohagen F
    J Clin Psychopharmacol; 2008 Oct; 28(5):550-4. PubMed ID: 18794652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
    Askari S; Mokhtari S; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
    BMC Psychiatry; 2022 Jan; 22(1):34. PubMed ID: 35022014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial.
    Paydary K; Akamaloo A; Ahmadipour A; Pishgar F; Emamzadehfard S; Akhondzadeh S
    J Clin Pharm Ther; 2016 Apr; 41(2):214-9. PubMed ID: 26931055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder.
    Shapira NA; Ward HE; Mandoki M; Murphy TK; Yang MC; Blier P; Goodman WK
    Biol Psychiatry; 2004 Mar; 55(5):553-5. PubMed ID: 15023585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.
    Greist JH; Jefferson JW; Kobak KA; Katzelnick DJ; Serlin RC
    Arch Gen Psychiatry; 1995 Jan; 52(1):53-60. PubMed ID: 7811162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.